Cancer treatment is slowly shifting away from the standard chemo and radiation and more towards immunotherapy as an alternative treatment. Unlike chemotherapy which destroys healthy, rapidly dividing cells in the body, immunotherapy is more targeted, using the patient’s own immune system to fight cancer. Chemotherapy’s attack on healthy cells causes the well known side effects
Read More
Biopharma company Imugene (ASX: IMU) is now on their way towards commercialisation of their lung cancer treatment with approval from the US Food and Drug Administration (FDA) to commence human trials. With the project name PD1-Vaxx in the US, the approval enables Imugene to commence recruiting patients for a clinical trial of the treatment on
Read More